Enhanced Protein-Based COVID-19 Vaccine Approved in the UK and Singapore – Precision Vaccinations

(Precision Vaccinations News)

Novavax, Inc. today announced that its prototype COVID-19 vaccine Nuvaxovid, was granted full approvalfor active immunization to prevent COVID-19 inindividuals aged 12 and older by Singapore'sHealth Sciences Authority (HSA) and the U.K.Healthcare products Regulatory Agency (MHRA).

In recent clinicaltrials, the protein-basedNuvaxovid(NVX-CoV2373) vaccine demonstrated the efficacy and safety of its prototype vaccine as a primary series in individuals aged 12 and older and the immunogenicity and safety of the vaccine as a booster in individuals aged 18 and older.

"Full marketing authorization of our prototype COVID-19 vaccine in the U.K. is a stepping stone to enable authorization of updated strains of our vaccine in the future," saidJohn C. Jacobs, President and Chief Executive Officer, Novavax, in a press release on October 18, 2023.

"We are working with the MHRA to provide the information needed for the rapid review of our updated protein-based non-mRNA COVID-19 vaccine as an important step to ensuring access to vaccine options in the U.K. this coming vaccination season."

Novavax Inc.'svaccinesare genetically engineered usingthree-dimensionalnanostructures ofrecombinant proteinscritical to diseasepathogenesis.

While authorized in the U.S., the trade name Nuvaxovid has not been approved by the U.S. Food and DrugAdministration (FDA).

OnOctober 3, 2023, the FDA amended its authorization of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 and older, to include the2023-2024 formula.

Since December 2021,Novavax's COVID-19 vaccines have been distributed in about 40 countries.

Original post:

Enhanced Protein-Based COVID-19 Vaccine Approved in the UK and Singapore - Precision Vaccinations